Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Rhea-AI Summary
Hemogenyx Pharmaceuticals (LSE:HEMO) announced the exercise of warrants for 250,000 new ordinary shares. The warrants, originally granted on May 8, 2025, had their exercise price adjusted to 180p per share, resulting in subscription monies of £450,000 received by the company.
Following admission of these shares and including the previously announced 316,667 new ordinary shares from August 26, 2025, the company's total issued shares and voting rights will increase to 5,293,896. The new shares are expected to be admitted to trading on the LSE main market on September 9, 2025.
Positive
- Receipt of £450,000 in subscription monies from warrant exercise
- Expansion of shareholder base through warrant conversion
Negative
- Dilution of existing shareholders due to new share issuance
- Downward adjustment of warrant exercise price from original terms
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK / ACCESS Newswire / September 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received a notice to exercise warrants over 250,000 new ordinary shares in the Company (the "Warrant Shares").
The Warrant Shares are being issued pursuant to the exercise of warrants granted and announced on 8 May 2025. As announced, the exercise price of the warrants ("Exercise Price") is subject to adjustment in certain circumstances, as set out in the warrant instrument, including a reset of the Exercise Price (as defined therein) if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period (as defined therein) at a price lower than the Exercise Price. As such, the Exercise Price was adjusted to 180p. Subscription monies of
Admission and Total Voting Rights
Application will be made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to theFCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 9 September 2025 ("Admission").
Upon Admission (and including the 316,667 new ordinary shares being issued as announced on 26 August 2025), the total number of issued shares and the total number of voting rights in the Company will be 5,293,896.
The above figure of 5,293,896 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
How many new shares will be issued through the Hemogenyx warrant exercise?
What is the adjusted exercise price for Hemogenyx's warrants?
How much capital did Hemogenyx raise from the warrant exercise?
What will be Hemogenyx's total number of shares after the warrant exercise?
When will the new Hemogenyx warrant shares begin trading?
